George,
Thought you would be interested in a communication I had on the Hemisperix thread.http://www.exchange2000.com/~wsapi/investor/Subject-17968
Subject: HEB, Hemispherx Biopharma (AMEX)NEW
| Previous | Next | Respond |
To: dan byrne (71 )
From: Marc Goldschmidt Tuesday, Nov 18 1997 2:17PM EST
Reply #73 of 75
Hi Dan-
Verification of the partnership agreements can be found at the following sources:
hemispherx.com
hemispherx.com
According to the HEB (HEMX at that time) 3rd qtr.
1996 report:
In Feb. 1996, the Co. (HEB) entered into an agreement with Helix BioPharma, a Canadian based pharmaceutical and biomedical co., to jointly develop the Co.s' (HEB) lead product for certain chronic viral disorders and diseases of immunological dysregulation. Helix BioPharma is the parent co. of Rivex Pharma, Inc., with which the Co. (HEB) has an agreement for marketing and distribution services in Canada. Helix BioPharma,
headquartered in Richmond, British Columbia, is developing, licensing, marketing, and distributing
biomedical and pharmaceutical products and services principally to the Canadian markets.
In May 1996, the Canadian Health Protection Board
authorized Helix BioPharma Corp. (HELIX) of British Columbia, to supply Ampligen under the Canadian Emergency Drug Release Prograam. This authorization means that the drug will be available in Canada to sufferers of HIV and Chronic Fatigue Syndrome. The
Co. (HEB) is in the process of producing Ampligen doses for shipment to Helix for distribution and
sales in Canada."
Dan, In the U.S., the drug is only available in various clinical trials. The CFS trial is in its late stages (phase III), and some results are
expected this quarter. Hopefully, if positive,
an NDA will move HEB or licensed partners forward to publically supply Ampligen stateside.
I hope this answered your questions.
MG:
| Previous | Next | Respond |
View SubjectMarksBookmark this Subject
Return to Biotechnology
One or more words separated by spaces:
Subject Titles Only
Full-Text
Messages with Links
Send questions and feedback to webmistress@techstocks.com
Terms of Use |
